Pipeline

A pipeline of neuroprotectants for multiple indications, Avilex’ lead compound, AVLX-144, is entering Phase 2 clinical trials, and a range of new preclinical assets are being developed

Compound(s)

Lead Optimization

Non-Clinical

Regulatory Toxicology

Phase I

Phase II

Phase III


AVLX-144


Carefully optimized, unique structure


Extensively characterized in stroke in vivo models


Completed full toxicology package


Completes clinical trial Phase I




2nd GenerationPSD-95 Inhibitors


New potent inhibitors with unique properties


In vivo characterization ongoing






PSD-95 PET TracerClinical Biomarker Studies


Highly promising PSD-95 biomarker developed


In vivo characterization ongoing






Cyclic PeptidePSD-95 Inhibitors


Novel, potent cyclic peptide inihibtors developed






AVLX-144

Lead Optimization


Carefully optimized, unique structure

Non-Clinical


Extensively characterized in stroke in vivo models

Regulatory Toxicology


Completed full toxicology package

Phase I


Completes clinical trial Phase I

Phase II


Phase III


2nd Generation

PSD-95 Inhibitors

Lead Optimization


New potent inhibitors with unique properties

Non-Clinical


In vivo characterization ongoing

Regulatory Toxicology


Phase I


Phase II


Phase III


PSD-95 PET Tracer

Clinical Biomarker Studies

Lead Optimization


Highly promising PSD-95 biomarker developed

Non-Clinical


Extensively characterized in stroke in vivo models

Regulatory Toxicology


Phase I


Phase II


Phase III


Cyclic Peptide

PSD-95 Inhibitors

Lead Optimization


Highly promising PSD-95 biomarker developed

Non-Clinical


Regulatory Toxicology


Phase I


Phase II


Phase III


Last update

21 Nov - 2020

Successfully completes phase 1 clinical trial

Avilex Pharma successfully completes its phase 1 clinical trial of AVLX-144 – A potentially game-changing treatment for acute neurological conditions

Avilex Pharma, a clinical stage biotechnology company developing innovative treatments for acute neurological conditions such as acute ischemic stroke (AIS) and subarachnoid haemorrhage (SAH), is excited to announce the successful completion of the company’s first-in-human Phase 1 clinical trial of its lead compound AVLX-144. During the course of the Phase I study, AVLX-144 was well-tolerated and demonstrated no noteworthy safety issues related to treatment  The result provides a solid foundation for Avilex’s transition into later phase clinical trials to further study the compound’s efficacy.

Get in touch